Robertl Nussbaum News Today

Shares of Invitae Co. (NYSE:NVTA – Free Report) have been given a consensus recommendation of “Reduce” by the eleven analysts that are currently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a sell rating and six have issued a hold rating on the company. The average 12 month target […]

Nikko Asset Management Americas Inc. lessened its holdings in Invitae Co. (NYSE:NVTA – Get Rating) by 0.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 17,256,161 shares of the medical research company’s stock after selling 19,190 shares during the period. Nikko Asset Management Americas Inc. owned approximately 0.07% of Invitae worth $32,096,000 as […]

Swiss National Bank increased its holdings in Invitae Co. (NYSE:NVTA – Get Rating) by 4.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 539,600 shares of the medical research company’s stock after buying an additional 23,100 shares during […]

Stock analysts at StockNews.com assumed coverage on shares of Invitae (NYSE:NVTA – Get Rating) in a research note issued on Thursday. The firm set a “sell” rating on the medical research company’s stock. A number of other research analysts also recently commented on the company. The Goldman Sachs Group downgraded Invitae from a “neutral” rating […]

Invitae (NYSE:NVTA – Get Rating) had its price target decreased by Piper Sandler from $1.75 to $1.50 in a research report released on Monday, The Fly reports. A number of other analysts have also weighed in on the stock. StockNews.com began coverage on shares of Invitae in a research note on Thursday, March 16th. They […]

Invitae Co. (NYSE:NVTA – Get Rating) insider Robert L. Nussbaum sold 26,476 shares of the company’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $1.20, for a total value of $31,771.20. Following the completion of the sale, the insider now owns 576,431 shares of the company’s […]

Invitae (NYSE:NVTA – Get Rating) announced its quarterly earnings data on Tuesday. The medical research company reported ($0.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by ($0.02), MarketWatch Earnings reports. The company had revenue of $123.70 million during the quarter, compared to analysts’ expectations of $129.31 million. Invitae had a […]

Wall Street analysts expect Invitae Co. (NYSE:NVTA – Get Rating) to report sales of $126.72 million for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Invitae’s earnings. The highest sales estimate is $127.95 million and the lowest is $125.30 million. Invitae reported sales of $103.62 million in the same quarter […]

Brokerages expect Invitae Co. (NYSE:NVTA – Get Rating) to report sales of $130.38 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Invitae’s earnings, with estimates ranging from $125.30 million to $138.81 million. Invitae posted sales of $103.62 million during the same quarter last year, which suggests a […]

Strs Ohio cut its holdings in Invitae Co. (NYSE:NVTA – Get Rating) by 80.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 4,500 shares of the medical research company’s stock after selling 18,900 shares during the period. Strs Ohio’s holdings in Invitae were worth $68,000 as of its most recent SEC filing. […]